Ulcerative Colitis Market
Ulcerative colitis is one of the most common type of inflammatory bowel diseases that affect the rectum and colon i.e. lining of the large intestine. Ulcerative colitis leads to tiny sores called ulcers. Although this disease can affect people of any age, the highest prevalence is among people aged 30 years and below. The most common symptoms of this disease include belly pain, cramps, bleeding from the rectum, diarrhea, and sudden weight loss, loss of appetite, eye disease, joint pain, and blood infection, thickening of the intestinal wall, liver disease, and even kidney stones. Furthermore, the primary diagnosis can be done with physical examination using colonoscopy, biopsy, endoscopy, blood test, and CT scan.
If ulcerative colitis extends for over 8 years, it could lead to colon cancer. Generally, people with mild symptoms of this diseases can be treated with OTC drugs such as Imodium therapy. However, prescribed medications such as amino salicylates and steroid medicines are typically use for its treatment. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps prevent colon cancer.
𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐈𝐬 𝐋𝐢𝐯𝐞!
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐨 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐭𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/238
Moreover, some genetically engineered drugs also used to treat ulcerative colitis. These drugs are made up of certain living organisms that help suppress the inflammation, by targeting the inflammatory proteins such as cytokines. Some genetically engineered drugs approved by the U.S. FDA for treatment of the condition are Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade) and Vedolizumab (Entyvio).
These genetically engineered drugs may show some side effects such as fever, headache, hives, low blood pressure, breathing difficulties, back pain, and stomach pain. Furthermore, these drugs may affect the immunity power of body to fight infection.
Although the exact reason for ulcerative colitis is unknown, potential causes may include genetic factors, weakened immune system, and environmental changes. According to data released by the Centers for Disease Control and Prevention (CDC), there are around 2.2 to 14.3 cases found per 100,000 population per year. Also, according to a study conducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA), 907,000 people suffered from ulcerative colitis in the U.S. (data based on the research conducted in between 2011-2014 by CCFA).
Ulcerative colitis market taxonomy:
Global Market by Drug Type
- Infliximab
- Golimumab
- Adalimumab
- Vedolizumab
- Mesalamine
- Budesonide
- Balsazide
Global Market by Dosage Form
- Parenteral
- Oral
Global Market by Geography
- North America
- Europe
- APAC
- Latin America
- Middle East
- Africa
To Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/238
Market Drivers
Rising prevalence of the ulcerative colitis in both developed and emerging economies is expected to drive growth of the global ulcerative colitis market during the forecast period. According to the study of CCFA, industrialized countries have highest incidence rate for ulcerative colitis. This disease is most prevalent in urban areas than in rural areas, also it can affect to any age group of people but most cases diagnosed are of the age in between 15 to 35. According the stats of World Gastroenterology Organization (WGO), there is rising incidence rate in emerging economies such as India. Due to changing diet and lifestyle pattern, the emerging economies will show high growth rate in incidence rate of ulcerative colitis in the near future.
Regional Insights
Among regions, North America holds dominant position in the global ulcerative colitis market, owing to growing awareness regarding the treatment, continuous enhancements in drugs, and increasing clinical research. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to rising awareness about the treatment, changing lifestyle, and growing prevalence of the disease. For example, in 2016, India-based Torrent Pharmaceuticals launched a biosimilar drug under the brand name Adfra to compete Humira. Humira is a trade name for adalimumab medication owned by AbbVie Inc.
Competitive Section
Key companies operating in the global ulcerative colitis market are AbbVie Inc., Hospira, Celltrion Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott, Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals Company Ltd.
Key Developments
- Key players in the market are focused on various growth strategies such research and development of novel products, in order to enhance their product portfolio. For instance, in October 2018, Pfizer, Inc.’s Xeljanz, an oral Janus kinase inhibitor showed effectiveness and safety in the treatment of ulcerative colitis in a 24-month open label extension study.
- Major companies in the market are involved in various business strategies such research and development of novel products, in order to enhance their product portfolio. For instance, in March 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Phase III data UNFI study data for Stelara, a subcutaneous maintenance therapy, which showed positive results as maintenance therapy in adults suffering from moderate to severe ulcerative colitis.
- Major companies in the market are involved in various growth strategies such research and development of novel products, in order to enhance their market presence. For instance, in August 2019, Takeda Pharmaceutical Company Limited, submitted new drug application (NDA) to Ministry of Health, Labour and Welfare in Japan for subcutaneous formulation of vedolizumab, which will be used as maintenance therapy in adults with moderate to severe ulcerative colitis.
For More Information or Query or Customization before Buying, Visit at – https://www.coherentmarketinsights.com/insight/talk-to-analyst/238
Table of Contents:
- Research Objective and assumption
o Research Objectives
o Assumptions
o Abbreviations - Market Overview
o Report Description
• Market Definition and Scope
o Executive Summary
• Market Snippet By Product Type
• Market Snippet By Application
• Market Snippet By Technology
• Market Snippet By End User
• Market Snippet By Region
o Coherent Opportunity Map (COM) - Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
• Drivers
• Restraints
• Market Opportunities
o Technological Trends
o PEST Analysis
o Impact Analysis - Global Ulcerative Colitis Market, By Product Type, 2021 – 2028 (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2028 (%)
• Y-o-Y Growth Analysis, 2021 – 2028
• Segment Trends
o Reagents & Consumables
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Software’s
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Instruments
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million) - Global Ulcerative Colitis Market, By Application, 2021 – 2028 (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2028 (%)
• Y-o-Y Growth Analysis, 2021 – 2028
• Segment Trends
o Genomics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Proteomics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Diagnostics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Drug Discovery
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million) - Global Ulcerative Colitis Market, By Technology, 2021 – 2028 (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2028 (%)
• Y-o-Y Growth Analysis, 2021 – 2028
• Segment Trends
o Microarrays
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Microfluidics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million) - Global Ulcerative Colitis Market, By End User, 2021 – 2028 (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2028 (%)
• Y-o-Y Growth Analysis, 2021 – 2028
• Segment Trends
o Hospitals
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Diagnostic Labs
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Academic & Research Institutes
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
o Biotechnology & Pharmaceutical Companies
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Million)
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837